妥洛特罗贴剂治疗支气管哮喘的有效性和安全性

Efficacy and safety of tulobuterol tape in asthma patients

目的了解妥洛特罗贴剂治疗支气管哮喘的有效性和安全性。方法共有91例轻中度持续哮喘患者入选本研究,妥洛特罗贴剂组46例,每贴2mg,每晚1次,多索茶碱片组45例,0.3g/次,2次/d。治疗4周后观察呼吸流量峰值(PEF)、症状评分、使用速效缓解药物的次数、哮喘控制测试表(ACT)评分及不良反应发生情况。结果治疗4周后,1妥洛特罗贴剂组日间症状评分较治疗前显著下降,差异有统计学意义(P<0.05),且较对照组明显下降,差异有统计学意义(P<0.05);妥洛特罗贴剂夜间症状评分较治疗前显著下降,差异有统计学意义(P<0.05),但较对照组下降不明显;2妥洛特罗贴剂组使用速效缓解药物次数较治疗前显著下降,差异有统计学意义(P<0.05),但较对照组下降不明显;3妥洛特罗贴剂ACT评分较治疗前显著增加,差异有统计学意义(P<0.05),较对照组明显增加,差异有统计学意义(P<0.05);4治疗2周及4周后,妥洛特罗贴剂组晨间及睡前PEF均较治疗前显著增加,差异有统计学意义(P<0.05),且较对照组也明显增加;试验期间妥洛特罗贴剂组未出现不良事件,对照组出1例心悸。结论妥洛特罗贴剂是一种安全、有效的哮喘治疗药物。

Objective To evaluate the efficacy and safety of tulobuterol tape in asthma patients. Methods A total of 91 adults patients with mild and moderate persistent asthma were enrolled, 46 patients were treated with tulobuterol tape and 45 patients with doxofyline tablet. Results After 4 weeks of treatment, the daytime symptoms scores, night symptoms scores and usage of short - acting 132 agonist in the tulobuter tape groups were decreased significantly （ P 〈 0.05 ） , but the differences of night symptoms scores or usage of short - acting 132 agonist were not significant between the two groups, respecttively, the morning peak expiratory flow（ PEF）, evening PEF and asthma control test scores （ACT） in the tulobuterol tape groups were increased significantly as compared to the doxofyline tablet groups（ P 〈 0. 05 ）. One patient developed palpitation in the doxofyline tablet group, while no adverse event occurred in the tulobuter tape group. Conclusion Tulobuter tape is a effective and safe medication for the treatment of asthma